The FDA has approved Genentech’s Rituxan Hycela for subcutaneous injection for the treatment of certain blood cancers. Rituxan Hycela has similar outcomes as Rituxan, but can be delivered in 5 to 7 ...

The subcutaneous injection is for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The Food and Drug Administration (FDA) has approved Rituxan ...

Pemphigus vulgaris is a potentially fatal autoimmune mucocutaneous blistering disease. Conventional therapy consists of high-dose corticosteroids, immunosuppressive agents, and intravenous immune ...

Hyperthyroidism in Graves' ophthalmopathy results from B-cell-mediated production of autoantibodies against the TSH receptor (anti-TSHR antibodies), and levels of these autoantibodies correlate with ...

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma Authors retain all rights in ...

Genentech, a member of the Roche Group announced Thursday that the U.S. Food and Drug Administration (FDA) approved RITUXAN HYCELA™ (rituximab and hyaluronidase human) for subcutaneous (under the skin ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved RITUXAN ...

Updates from the annual ASH meeting, December 2018. The launch of biosimilar rituximab is an eagerly awaited event among US healthcare stakeholders who are cognizant of the high cost of intravenous ...

September 11, 2008 — The safety labeling for rituximab intravenous infusion (Rituxan, Genentech, Inc, comarketed with Biogen Idec, Inc) has been updated to reflect a fatal case of progressive ...

NEW ORLEANS -- In a randomized comparison, rituximab (Rituxan) proved non-inferior to cyclosporine for the treatment of idiopathic membranous nephropathy, a researcher reported here. Preliminary ...